The trials of Juno

the-trials-of-juno

IN THE pharma business, Juno Therapeutics, a small firm based in Seattle, is just a stripling. It is three years old, has not a single drug approval to its name but is nonetheless valued at $2.8 billion. That value is derived from the fact that it is on the forefront of the most promising area of cancer treatments in decades: immuno-oncology.

Read more here.


Leave a Reply

Your email address will not be published. Required fields are marked *


Home / Cancer Left / The trials of Juno